Promis Valuation outlookHowever, various sources indicate that it can cost more than $1 billion to bring one product to the market, including approximately $50-840 million to bring treatments through the stages of Basic Research/Drug Development and Pre-Clinical/Translational Research.
You have to look at the average cost, not a specific Companies cost to evaluate the average cost to get to clinical trials. If successful on a phase one without major side effects I will say the market cap will be 4 Billion, for Canadians that is 5 Billion. The market value for a very compelling AD therapeutic is pegged anywhere from 12 - 25 Billion in annual sales. Adunucanumab is restricted by the FDA on its market and of course by its efficacy.
M101, yes I was very critical about the management under Goldstein and his pathetic financings and lies that never stop. The FSG group are serious people and are here to see this to the end, does that not mean a buyout could happen, of course. With them holding a control position and financing in place to see PMN310 to the clinic, do you think they would let any Company take this over cheap? Not on your life. Now lets get a powerhouse CEO and watch this skyrocket. For those ill informed weak investors, sell and buy mutual funds.